Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | CASP3 | P42574 | 3/20 | 1.00 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 1.00 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 1.00 |
| ▸ | NSD2 | O96028 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29539676 | 1.00 | NPC1 (1.00) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL410347 | 1.00 | NPC1 (1.00) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL26712504 | 0.82 | NPC1 (0.69) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL30471681 | 0.82 | NPC1 (0.69) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL10814151 | 0.82 | NPC1 (0.69) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL30332449 | 0.82 | MEN1 (0.67) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL30102207 | 0.82 | MEN1 (0.67) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL11981455 | 0.82 | MEN1 (0.67) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL1405327 | 0.82 | MEN1 (0.67) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL1405329 | 0.82 | MEN1 (0.67) | NPC1RAB9AKMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664334-B1 | METHOD AND DEVICE FOR DETERMINING IF A PRODUCT IS IN CONDITION FOR USE OR CONSUMPTION | CRYOLOG S A (FR) | 2012-04-18 | — | — | EP | claimed |
| JP-4834547-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| US-7960176-B2 | Method and device for determining if a product is in condition for use or consumption | CRYOLOG SA (FR) | 2011-06-14 | — | — | US | claimed |
| US-7588878-B2 | Inkless printing paper and method | XEROX CORPORATION (US) | 2009-09-15 | — | — | US | claimed |
| US-7553603-B2 | Inkless printing paper and method | XEROX CORPORATION (US) | 2009-06-30 | — | — | US | claimed |
| US-20080311518-A1 | INKLESS PRINTING PAPER AND METHOD | XEROX CORPORATION (US) | 2008-12-18 | — | — | US | claimed |
| US-20080311517-A1 | INKLESS PRINTING PAPER AND METHOD | XEROX CORPORATION (US) | 2008-12-18 | — | — | US | claimed |
| EP-2003503-A1 | Inkless printing paper and method | Xerox Corporation (US) | 2008-12-17 | — | — | EP | claimed |
| US-20070275467-A1 | Method and Device for Determining if a Product is in Condition for Use or Consumption | CRYOLOG S.A. (FR) | 2007-11-29 | — | — | US | claimed |
| EP-1664334-A1 | METHOD AND DEVICE FOR DETERMINING IF A PRODUCT IS IN CONDITION FOR USE OR CONSUMPTION | Cryolog S.A. (FR) | 2006-06-07 | — | — | EP | claimed |
| WO-2005026383-A1 | METHOD AND DEVICE FOR DETERMINING IF A PRODUCT IS IN CONDITION FOR USE OR CONSUMPTION | CRYOLOG S.A. (FR) | 2005-03-24 | — | — | WO | claimed |
| US-20220202861-A1 | TREATMENT OF LIVER FAILURE BY EX VIVO REPROGRAMMED IMMUNE CELLS | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-20210115489-A1 | NOVEL MEDIATOR | KIKKOMAN CORPORATION (JP) | 2021-04-22 | — | — | US | disclosed |
| US-20210115489-A1 | NOVEL MEDIATOR | KIKKOMAN CORPORATION (JP) | 2021-04-22 | — | — | US | disclosed |
| US-20200171088-A1 | TREATMENT OF LIVER FAILURE WITH ACTIVATED T REGULATORY CELLS | Viera Bioscience, Inc. | 2020-06-04 | — | — | US | disclosed |
| EP-0253325-A2 | Oncogene-related peptides | Yanaihara, Noboru (JP) | 1988-01-20 | — | — | EP | disclosed |
| US-4678436-A | Color-changeable cement composition for dental use | G-C DENTAL INDUSTRIAL CORP. (JP) | 1987-07-07 | — | — | US | disclosed |
| EP-0024202-B1 | 2,3,4,5,6-PENTA-O-ACETYL-D-GLUCONYL ISOTHIOCYANATE FOR USE IN PREVENTING AND TREATING CANCER | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1983-07-20 | — | — | EP | disclosed |
| US-4357349-A | 2,3,4,5,6-PENTAACETYL GLUCONYL ISOTHIOCYANATE | NITTO CHEMICAL INDUSTRY CO. (JP) | 1982-11-02 | — | — | US | disclosed |
| EP-0024202-A1 | 2,3,4,5,6-Penta-O-acetyl-D-gluconyl isothiocyanate for use in preventing and treating cancer | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1981-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115489-A1 | NOVEL MEDIATOR | MPO, EPX, LPO | NPC1 4474/4885RAB9A 3686/4885KMT2A 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.